MUNICH, Germany -- Leading experts called for immediate improvements in the diagnosis and treatment of Clostridium difficile-associated disease (CDAD) to contain the spread of this serious hospital-acquired diarrhea. CDAD is increasing in incidence and severity in the
CDAD, the most common form of hospital-acquired diarrhea, affects more than 500,000 people in the United States(1) and one out of every 1,000 patients hospitalized in Europe as of 2005.(2) The increased incidence and severity of the disease, coupled with an increase in treatment failures with standard therapies,(3) is a growing concern among public health officials, infectious diseases physicians, gastroenterologists, microbiologists and epidemiologists.
Data from the symposium, Clostridium Difficile-Associated Disease: Underdiagnosed, Underreported, Undertreated; How to Overcome the Challenges, confirmed the emergence and spread of a new virulent epidemic strain of CDAD known as North American Phenotype 1/027 (NAP1/027).
Todays growing CDAD epidemic is characterized by the emergence of a highly virulent and resistant strain, increases in incidence and severity of infection, increases in failed responses to existing therapies, and a growing number of recurrences following treatment. These problems all contribute to a rise in healthcare costs associated with treating CDAD, said Ed Kuijper, MD, PhD, vice president of the European Society of Clinical Microbiology and Infectious Diseases, professor of medical microbiology at the Leiden University Medical Center, and co-chair of the ECCMID symposium sponsored by Optimer Pharmaceuticals. Increased surveillance in hospitals and healthcare facilities, along with new approaches for diagnosing and treating patients, is urgently needed to combat this rapidly emerging infectious disease.
According to a presentation by Kuijper, 13 hospitals were monitored for CDAD in the Netherlands. An average of 17 per 10,000 patients (87 patients) admitted acquired CDAD, and two patients died as a result of CDAD. Early and rapid diagnosis, strict hand hygiene with soap and water, the use of gloves and aprons, grouping patients with CDAD, effective environmental cleaning with chlorine containing disinfectants, banning the use of fluoroquinolones and restricting the use of cephalosporins, were shown to help mitigate the further spread of the disease.
Frédéric Barbut, PharmD, PhD, an infection control practitioner working in the Infection Control Unit of Hôpital Saint-Antoine in Paris, France, and his colleagues, in collaboration with the Institut de Veille Sanitaire and regional coordinating centers, strengthened the surveillance of CDAD and built a network of regional laboratories for C. difficile characterization to promptly detect and control CDAD outbreaks in
The emergence and spread of the hypervirulent North America Phenotype 1/027 (NAP1/027) strain of CDAD in the United States, Canada and in some European countries call for improved rapid diagnosis, including the determination of C. difficile antibiotic resistance. Elisabeth Nagy, MD, PhD, DSc, professor at the Institute of Clinical Microbiology, and a member of the medical faculty at the University of Szeged in Hungary, presented how molecular typing methods help track the spread of C. difficile in hospitals and the community, including real-time PCR, which is a rapid method used to detect the gene directly from feces in symptomatic patients and asymptomatic carriers.
According to Dale N. Gerding, MD, a professor in the Department of Medicine at Loyola University Stritch School of Medicine, and associate chief of staff for research and development at the Hines VA Hospital in Illinois, patients prescribed metronidazole experienced poor response to therapy and high rates of recurrence following treatment. He further presented that patients prescribed vancomycin, the only FDA approved product to treat CDAD, also experienced high rates of recurrence following treatment. New agents, such as antimicrobials and monoclonal antibodies, are under development and show promise for the treatment and prevention of CDAD. Among the promising therapies under evaluation are gastrointestinal flora-sparing antibiotics, Difimicin and Rifaximin, and a toxin binder, Tolevamer.
Finally, C. difficile results in significant economic consequences for hospitals, healthcare providers and patients, including increased costs and prolonged hospital stays. Peter G. Davey, MD, a professor at the Health Informatics Centre at the University of Dundee in Dundee, Scotland, presented data showing that patients in the intensive care unit (ICU) who contracted CDAD stayed in ICU for 6.1 days as compared to three days for patients with no CDAD. ICU costs increased to $11,353 vs. $6,028 for patients with no CDAD.
1. Centers for Disease Control and Prevention (CDC)
2. ESCMID Study Group Report: A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Micro Infect. Vol. 9 Issue 10: 989, October 2003.
3. McDonald LC, et. al (2005). An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 243341.
Source: Optimer Pharmaceuticals